New Research from ProSites: 2023 Dental Marketing Trends

by Samuel Pordengerg Nov 22, 2022 News
New Research from ProSites: 2023 Dental Marketing Trends

PR NewswirePR Newswire

The research is underway for the State of Dental Marketing Report by ProSites. In order to better understand the current state of the dental industry and to serve as a guide for practices to stay competitive and up to date with the latest dental marketing trends, the annual report was launched in 2022.

ProSites, a national leader in dental practice marketing, communication, and efficiency software has just announced that research is currently underway for its 2023 State of Dental Marketing Report The ProSites State of Dental Marketing Report was launched in order to better understand the current state of the dental industry and the effects of the COVID-19 Pandemic.

Do you work in the dental industry? Participate in the study

With patients increasingly turning online to find and research healthcare providers, the report found that dental practices were following suit. In the midst of a global Pandemic, ProSites found that.

  • 34% of respondents reported annual practice revenue of more than a million dollars.

  • Heading into the year 2022, online marketing techniques were the most important.

  • In 2021, dental marketing budgets hit an all-time high, with 20% of respondents indicating they would increase marketing spend even further.

Here, you can access the complete study.

The Chief Revenue Officer at ProSites wanted to understand how practices cater to digital consumers. The State of Dental Marketing Report allowed us to compare the strategies of top performing practices with the rest of the sample to see what worked and what didn't.

The full report of the State of Dental Marketing Report will be aired in early 2023.

Tiffany Isbell said that the response from the dental community has been amazing. Over 1,700 practices have already responded to our report for next year, and we started with just over 100.

The state of dental marketing report is part of the process of participation.

The dental community is invited to take part in the research for the report. To serve as a guiding light for practices to stay competitive and up to date with the latest dental marketing trends, the company's vision is for this annual research project.

Take the survey

About Pro sites.

Dental and medical professionals can use innovative website design and digital marketing solutions from ProSites. Ready-to-go and custom website design, search engine marketing, social media management, automated patient communications, and pay-per-click services are included in the ProSites comprehensive suite of solutions. ProSites is endorsed by fifteen state dental associations. Call or visit to learn more about the company.

You can contact the media.

Tiffany Isbell works for

ProSites is a source of information.

  • One boss estimated his loss at half a million dollars because workers are lying about being digital nomads.

  • Veru, a company that looks for novel cancer therapies, saw its share price fall on Monday. The company's stock lost $10 a share when the FDA advisory panel voted against approving the oral therapy via the emergency use authorization route. The FDA usually agrees with advisory panel's votes.

  • Bob Iger is the CEO of Disney.

  • The entertainment industry was surprised by Bob Iger's return as the CEO of the Disney Company on Sunday night. A $1 million base salary will be earned by the former Disney CEO when he returns to his previous job. The pact could grow richer if Iger and Iger were to join.

  • The Saudis and Russians are not going to sit back and allow the market collapse to continue. In an urgent response to a Wall Street Journal story on Monday, the Saudi Energy Minister denied that the oil producing alliance under his charge was working on a production hike of 500,000 barrels per day. The WSJ report would have pivoted the 2-million-barrel per day cut announced by the Organization of the Petroleum Exporting Countries.

  • Financial planners advise you to work as long as you can so that you can get a bigger Social Security check. Retiring early, even at full retirement age, is a joke for those tens of millions. Millions of people have to keep working, even if they don't want to, because companies refuse to shift the finances of retirement off their balance sheets and onto the backs of their workers.

  • A lawsuit accusing the company of violating U.S. law by laying off thousands of workers without notice is baseless, and should be sent to arbitration, according to the company. The class action was brought under a federal law that requires 60 days' notice before mass layoffs. Since the acquisition of the company by Musk, 3,700 employees have been laid off and hundreds more have left.

  • There were problems with some of the machines it had replaced. According to the FDA, the company notified them that the new silicone sound abatement foam may separate from the plastic backing and block the air inlet.

  • Most people should wait until they're 65 to claim their full Social Security benefits.

  • The shares of MacroGenics were down more than 18%. The company's shares rose last week when it was announced that a $60 million milestone payment was coming its way after the FDA approved teplizumab to delay the start of type 1 diabetes. The drug was bought by Provention Bio.

  • It is a great goal to save a million dollars for retirement. It would be easier to live your lifestyle when you retire if you put that much away. What percentage of retirees have a million dollars?

  • The FDA requested that the US marketing authorization for Blenrep be withdrawn. The DREAMM-3 Phase 3 confirmatory trial did not meet the requirements of the FDA and therefore this request was made. Adult patients with multiple myeloma who have received at least four previous therapies can benefit from Blenrep. Also watch.

  • Nobody with a "familial relationship" with SBF would be paid by FTX.

  • The chairman of the media and entertainment distribution segment is leaving.

  • There was a year to forget for the Biotech stock market. A mix of profit-taking, clinical setbacks, a stricter Food and Drug Administration, as well as rising interest rates and good old fashioned risk aversion sent the SPDR S&P Biotech exchange traded fund plunging downward this year. Through the first 11 months of the year, the S&P Biotech exchange traded fund plummeted by over 50% from its prior three-year high.

  • According to reports, China will impose a fine of more than $1 billion on Jack Ma's company after two years of regulatory wrangling. The central bank of China is readying a fine for its actions after the administration scuttled the company's IPO at the last minute. A man named Warren Bu.

  • Christine McCarthy told the directors of her lack of confidence in the CEO.

  • There are two ongoing trials evaluating the lead targeted radio therapy, rhenium (186Re) sbemeda, in recurrent glioblastoma. In 24 patients with recurrent glioblastoma, a single dose of rhenium (186Re) sbemeda was administered in the dose escalation phase, achieving up to 740 Gray of absorbed radiation.

  • The data supports moving ahead with NASH clinical studies. There are two concurrent Phase 3 studies of ORMD-0801) for the treatment of T2D and NASH. We believe in multiples.

  • The company is specialized in cancer therapies. On Monday, its stock got a boost after ponatinib hit its primary goal in a phase 3 trial. The blood cancer therapy works by slowing the activity of BCR-ABL1, a gene sequence that is often seen in people with leukemia.